Actively Recruiting
IMPT Dose Escalation for NSCLC (HyDose)
Led by University Medical Center Groningen · Updated on 2026-01-30
87
Participants Needed
1
Research Sites
160 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
The goal of this clinical pilot trial is to learn if dose to the tumor in the lung can be safely increased using proton therapy in stage III non-small-cell lung cancer patients receiving combined chemotherapy and radiotherapy. The main questions it aims to answer are: * Is the risk of severe radiotherapy toxicities (requiring hospital admission) within acceptable margins ? * What is a rough estimate of the effect of the treatment under study? Compared to standard care in our clinic, all participants in this pilot trial will * Receive a higher dose of proton therapy to the tumor in the lung albeit with the same number of radiotherapy visits as the current standard treatment. * Receive two additional follow-up visits at the clinic after treatment, namely 4 and 6 weeks after finishing radiotherapy. * Two additional blood withdrawals at the last week of radiotherapy and 4 weeks after finishing radiotherapy, to measure a type of white blood cells. * Receive an extra quality of life questionnaire at the last week of radiotherapy.
CONDITIONS
Official Title
IMPT Dose Escalation for NSCLC (HyDose)
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Age 18 years or older
- WHO performance score of 0 to 2
- Histologically confirmed stage III non-small-cell lung cancer
- Planned to receive concurrent chemoradiotherapy and adjuvant immunotherapy
- Primary tumor volume mostly outside the mediastinal planning risk volume (at least 60%)
You will not qualify if you...
- Chemotherapy not given at the same time as radiotherapy
- Decision made before treatment that adjuvant immunotherapy is not possible
- Primary tumor overlapping 40% or more with the mediastinal planning risk volume
- Unable or unwilling to understand trial information, give consent, or complete quality-of-life questionnaires
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
UMCG
Groningen, Netherlands
Actively Recruiting
Research Team
A
A. Hessels, MD PhD
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
TREATMENT
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here